Eagle Asset Management’s AnaptysBio ANAB Stock Holding History

Eagle Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,179	Closed	-$25K	–	595
2020 Q4	$25K	Buy	+1,179	New	+$28.6K	﹤0.01%	554

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eagle Asset Management's ANAB Position: Q1 2021 in Review

Eagle Asset Management sold out of AnaptysBio (ANAB) in Q1 2021, closing a stake of 1,179 shares — an estimated $25K sold.

Eagle Asset Management first reported a position in ANAB in Q4 2020 and held it in 1 quarter. The position peaked at $25K in Q4 2020. 122 funds tracked by Wall St. Rank hold ANAB as of Q1 2021.

Eagle Asset Management reported no remaining AnaptysBio position as of Q1 2021 after selling out during the quarter.
Eagle Asset Management sold 1,179 AnaptysBio shares in Q1 2021, an estimated $25K.
Eagle Asset Management first reported a position in AnaptysBio in Q4 2020 and held it in 1 quarter.
Eagle Asset Management's AnaptysBio position peaked at $25K in Q4 2020.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2021.

Based on Eagle Asset Management's 13F filing for Q1 2021, filed 14 May 2021.